Analysts predict that Markel Co. (NYSE:MKL) will post sales of $1.58 billion for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Markel’s earnings. The highest sales estimate is $1.66 billion and the lowest is $1.54 billion. Markel reported sales of $1.43 billion in the same quarter last year, which would suggest a positive year over year growth rate of 10.5%. The firm is expected to issue its next earnings report on Wednesday, February 14th.
On average, analysts expect that Markel will report full-year sales of $1.58 billion for the current financial year, with estimates ranging from $5.93 billion to $6.06 billion. For the next year, analysts expect that the firm will report sales of $6.39 billion per share, with estimates ranging from $6.12 billion to $6.81 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Markel.
Markel (NYSE:MKL) last released its quarterly earnings results on Wednesday, October 25th. The insurance provider reported ($18.82) EPS for the quarter, missing analysts’ consensus estimates of ($18.03) by ($0.79). Markel had a net margin of 1.60% and a return on equity of 0.83%.
In related news, Vice Chairman Steven A. Markel sold 200 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1,115.78, for a total value of $223,156.00. Following the completion of the transaction, the insider now directly owns 106,712 shares in the company, valued at $119,067,115.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alan I. Kirshner sold 100 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $1,133.50, for a total transaction of $113,350.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,307 shares of company stock valued at $2,535,956 over the last 90 days. Company insiders own 2.53% of the company’s stock.
A number of large investors have recently made changes to their positions in MKL. Comerica Bank grew its position in Markel by 1.4% in the second quarter. Comerica Bank now owns 590 shares of the insurance provider’s stock worth $603,000 after acquiring an additional 8 shares in the last quarter. Prudential Financial Inc. grew its position in Markel by 10.6% in the second quarter. Prudential Financial Inc. now owns 1,042 shares of the insurance provider’s stock worth $1,017,000 after acquiring an additional 100 shares in the last quarter. Neuberger Berman Group LLC grew its position in Markel by 0.5% in the second quarter. Neuberger Berman Group LLC now owns 428 shares of the insurance provider’s stock worth $418,000 after acquiring an additional 2 shares in the last quarter. JPMorgan Chase & Co. grew its position in Markel by 273.1% in the second quarter. JPMorgan Chase & Co. now owns 4,153 shares of the insurance provider’s stock worth $4,052,000 after acquiring an additional 3,040 shares in the last quarter. Finally, Schroder Investment Management Group purchased a new position in Markel in the second quarter worth $1,428,000. Institutional investors own 76.79% of the company’s stock.
Markel (NYSE:MKL) opened at $1,123.37 on Monday. The company has a market cap of $15,605.86, a price-to-earnings ratio of 249.64 and a beta of 1.04. The company has a current ratio of 0.55, a quick ratio of 0.55 and a debt-to-equity ratio of 0.28. Markel has a 1 year low of $612.00 and a 1 year high of $1,157.30.
Markel Corporation is a financial holding company serving a range of markets. The Company’s principal business markets and underwrites specialty insurance products. It monitors and reports its ongoing underwriting operations in three segments: U.S. Insurance, International Insurance and Reinsurance. The Company, through its subsidiary Markel Ventures, Inc (Markel Ventures), owns interests in various industrial and service businesses that operate outside of the specialty insurance marketplace.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Markel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Markel and related companies.